139 related articles for article (PubMed ID: 1548283)
1. The tumour-inhibiting potential of the progesterone antagonist Onapristone in the human mammary carcinoma T61 in nude mice.
Schneider MR; Michna H; Habenicht UF; Nishino Y; Grill HJ; Pollow K
J Cancer Res Clin Oncol; 1992; 118(3):187-9. PubMed ID: 1548283
[TBL] [Abstract][Full Text] [Related]
2. Tumor-inhibiting potential of ZK 112.993, a new progesterone antagonist, in hormone-sensitive, experimental rodent and human mammary tumors.
Schneider MR; Michna H; Nishino Y; Neef G; el Etreby MF
Anticancer Res; 1990; 10(3):683-7. PubMed ID: 2369083
[TBL] [Abstract][Full Text] [Related]
3. The antitumor mechanism of progesterone antagonists is a receptor mediated antiproliferative effect by induction of terminal cell death.
Michna H; Schneider MR; Nishino Y; el Etreby MF
J Steroid Biochem; 1989; 34(1-6):447-53. PubMed ID: 2626038
[TBL] [Abstract][Full Text] [Related]
4. The effect of onapristone, a progesterone antagonist, on the growth of human gastrointestinal cancer xenografts.
Jacobs E; Watson SA; Ellis IO; Hardcastle JD; Robertson JF
Eur J Cancer; 1997 Jun; 33(7):1130-5. PubMed ID: 9376194
[TBL] [Abstract][Full Text] [Related]
5. The antitumor potency of progesterone antagonists is due to their differentiation potential.
Michna H; Gehring S; Kühnel W; Nishino Y; Schneider MR
J Steroid Biochem Mol Biol; 1992 Sep; 43(1-3):203-10. PubMed ID: 1525061
[TBL] [Abstract][Full Text] [Related]
6. Antitumor activity and mechanism of action of different antiprogestins in experimental breast cancer models.
Schneider MR; Michna H; Nishino Y; el Etreby MF
J Steroid Biochem Mol Biol; 1990 Dec; 37(6):783-7. PubMed ID: 2285591
[TBL] [Abstract][Full Text] [Related]
7. Progesterone antagonists: tumor-inhibiting potential and mechanism of action.
Michna H; Nishino Y; Neef G; McGuire WL; Schneider MR
J Steroid Biochem Mol Biol; 1992 Mar; 41(3-8):339-48. PubMed ID: 1562510
[TBL] [Abstract][Full Text] [Related]
8. Inhibiting Nuclear Phospho-Progesterone Receptor Enhances Antitumor Activity of Onapristone in Uterine Cancer.
Huang Y; Hu W; Huang J; Shen F; Sun Y; Ivan C; Pradeep S; Dood R; Haemmerle M; Jiang D; Mangala LS; Noh K; Hansen JM; Dalton HJ; Previs RA; Nagaraja AS; McGuire M; Jennings NB; Broaddus R; Coleman RL; Sood AK
Mol Cancer Ther; 2018 Feb; 17(2):464-473. PubMed ID: 29237804
[TBL] [Abstract][Full Text] [Related]
9. Onapristone, a progesterone receptor antagonist, as first-line therapy in primary breast cancer.
Robertson JF; Willsher PC; Winterbottom L; Blamey RW; Thorpe S
Eur J Cancer; 1999 Feb; 35(2):214-8. PubMed ID: 10448262
[TBL] [Abstract][Full Text] [Related]
10. Antitumor activity of the progesterone antagonists ZK 98.299 and RU 38.486 in the hormone-dependent MXT mammary tumor model of the mouse and the DMBA- and the MNU-induced mammary tumor models of the rat.
Schneider MR; Michna H; Nishino Y; el Etreby MF
Eur J Cancer Clin Oncol; 1989 Apr; 25(4):691-701. PubMed ID: 2497018
[TBL] [Abstract][Full Text] [Related]
11. Antitumor effects of antiprogesterones on human meningioma cells in vitro and in vivo.
Matsuda Y; Kawamoto K; Kiya K; Kurisu K; Sugiyama K; Uozumi T
J Neurosurg; 1994 Mar; 80(3):527-34. PubMed ID: 8113866
[TBL] [Abstract][Full Text] [Related]
12. Antitumor activity of the antiprogestins ZK 98.299 and RU 38.486 in hormone dependent rat and mouse mammary tumors: mechanistic studies.
Michna H; Schneider MR; Nishino Y; el Etreby MF
Breast Cancer Res Treat; 1989 Dec; 14(3):275-88. PubMed ID: 2514814
[TBL] [Abstract][Full Text] [Related]
13. Modulation of oestrogenic effects by progesterone antagonists in the rat uterus.
Chwalisz K; Stöckemann K; Fritzemeier KH; Fuhrmann U
Hum Reprod Update; 1998; 4(5):570-83. PubMed ID: 10027611
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of the estradiol-mediated endometrial gland formation by the antigestagen onapristone in rabbits: relationship to uterine estrogen receptors.
Chwalisz K; Hegele-Hartung C; Fritzemeier KH; Beier HM; Elger W
Endocrinology; 1991 Jul; 129(1):312-22. PubMed ID: 2055191
[TBL] [Abstract][Full Text] [Related]
15. Effect of onapristone and medroxyprogesterone acetate on the proliferation and hormone receptor concentration of human breast cancer cells.
Classen S; Possinger K; Pelka-Fleischer R; Wilmanns W
J Steroid Biochem Mol Biol; 1993 Apr; 45(4):315-9. PubMed ID: 8499339
[TBL] [Abstract][Full Text] [Related]
16. Phase I study of onapristone, a type I antiprogestin, in female patients with previously treated recurrent or metastatic progesterone receptor-expressing cancers.
Cottu PH; Bonneterre J; Varga A; Campone M; Leary A; Floquet A; Berton-Rigaud D; Sablin MP; Lesoin A; Rezai K; Lokiec FM; Lhomme C; Bosq J; Bexon AS; Gilles EM; Proniuk S; Dieras V; Jackson DM; Zukiwski A; Italiano A
PLoS One; 2018; 13(10):e0204973. PubMed ID: 30304013
[TBL] [Abstract][Full Text] [Related]
17. Onapristone (ZK 98.299): a potential antiprogestin for endometrial contraception.
Katkam RR; Gopalkrishnan K; Chwalisz K; Schillinger E; Puri CP
Am J Obstet Gynecol; 1995 Sep; 173(3 Pt 1):779-87. PubMed ID: 7573244
[TBL] [Abstract][Full Text] [Related]
18. Induction of TGF-beta by an antiprogestin in the human breast cancer cell line T-47D.
Dannecker C; Possinger K; Classen S
Ann Oncol; 1996 Apr; 7(4):391-5. PubMed ID: 8805931
[TBL] [Abstract][Full Text] [Related]
19. Establishment and characterization of a new human oestradiol- and progesterone-receptor-positive mammary carcinoma serially transplantable in nude mice.
Naundorf H; Fichtner I; Büttner B; Frege J
J Cancer Res Clin Oncol; 1992; 119(1):35-40. PubMed ID: 1400563
[TBL] [Abstract][Full Text] [Related]
20. Effects of the progesterone antagonists onapristone (ZK 98 299) and ZK 136 799 on surgically induced endometriosis in intact rats.
Stoeckemann K; Hegele-Hartung C; Chwalisz K
Hum Reprod; 1995 Dec; 10(12):3264-71. PubMed ID: 8822456
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
